
News|Articles|December 1, 2001
FDA Actions in Brief
A once-daily, extended-release form of the amphetamine and dextroamphetamine mixture Adderall (Adderall XR, Shire) has been approved for treatment of attention-deficit/hyperactivity disorder. The new product is supplied in capsules that provide double-pulsed amphetamine delivery, prolonging the amphetamine release compared with immediate-release Adderall.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
WeightWatchers Launches Employer Program for GLP-1 Drugs
2
Real-World Data Shows Vision Decline as Copay Programs Run Dry | AAO 2025
3
Ergonomics, Independence and Inclusion Take Center Stage | AAO 2025
4
The Next Breakthrough in Schizophrenia Could be a Digital Therapeutic
5